Theravance Biopharma, Inc. (TBPH) shares recently surpassed the average analyst 12-month target price of $16.83, trading at $16.91 per share. This price movement indicates a potential reassessment from analysts regarding future price targets, which range from a low of $15.00 to a high of $21.00, with a standard deviation of $2.401 among six analysts covering the stock.
As of now, the breakdown of analyst ratings shows 4 strong buy ratings and 4 hold ratings, maintaining an average rating of 2.0 on a scale where 1 is strong buy and 5 is strong sell. Notably, no analysts currently hold sell or strong sell ratings for Theravance Biopharma.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
